BACKGROUND: The objective of this study was to evaluate the relation between the kinetics of prostate-specific antigen (PSA) decline after the initiation of androgen-deprivation therapy (ADT) and overall survival (OS) in men with metastatic, hormone-sensitive prostate cancer (HSPC). METHODS: The authors' institutional database was used to identify a cohort of men with metastatic HSPC who were treated with ADT. Patients were included if they had at least 2 serum PSA determinations before PSA nadir and at least 1 serum PSA value available within 1 month of ADT initiation. Patient characteristics, PSA at ADT initiation, nadir PSA, time to PSA nadir (TTN), and PSA decline (PSAD) in relation to OS were analyzed. RESULTS: One hundred seventy-nine patients were identified, and they had a median follow-up after ADT initiation of 4 years. The median OS after ADT initiation was 7 years. The median PSA level at ADT initiation and PSA nadir were 47 ng/mL and 0.28 ng/mL, respectively. On univariate analysis: TTN <6 months, PSAD >52 ng/mL per year, PSA nadir >or=0.2 ng/mL, PSA >or=47.2 ng/mL at ADT initiation, and Gleason score >7 were associated with shorter OS. On multivariate analysis, TTN <6 months, Gleason score >7, and PSA nadir >or=0.2 ng/mL independently predicted shorter OS. CONCLUSIONS: To the authors' knowledge, this was the first report to demonstrate that a faster time to reach a PSA nadir after the initiation of ADT was associated with shorter survival duration in men with metastatic HSPC. These results need confirmation but may indicate that a rapid initial response to ADT indicates more aggressive disease. (c) 2009 American Cancer Society.
BACKGROUND: The objective of this study was to evaluate the relation between the kinetics of prostate-specific antigen (PSA) decline after the initiation of androgen-deprivation therapy (ADT) and overall survival (OS) in men with metastatic, hormone-sensitive prostate cancer (HSPC). METHODS: The authors' institutional database was used to identify a cohort of men with metastatic HSPC who were treated with ADT. Patients were included if they had at least 2 serum PSA determinations before PSA nadir and at least 1 serum PSA value available within 1 month of ADT initiation. Patient characteristics, PSA at ADT initiation, nadir PSA, time to PSA nadir (TTN), and PSA decline (PSAD) in relation to OS were analyzed. RESULTS: One hundred seventy-nine patients were identified, and they had a median follow-up after ADT initiation of 4 years. The median OS after ADT initiation was 7 years. The median PSA level at ADT initiation and PSA nadir were 47 ng/mL and 0.28 ng/mL, respectively. On univariate analysis: TTN <6 months, PSAD >52 ng/mL per year, PSA nadir >or=0.2 ng/mL, PSA >or=47.2 ng/mL at ADT initiation, and Gleason score >7 were associated with shorter OS. On multivariate analysis, TTN <6 months, Gleason score >7, and PSA nadir >or=0.2 ng/mL independently predicted shorter OS. CONCLUSIONS: To the authors' knowledge, this was the first report to demonstrate that a faster time to reach a PSA nadir after the initiation of ADT was associated with shorter survival duration in men with metastatic HSPC. These results need confirmation but may indicate that a rapid initial response to ADT indicates more aggressive disease. (c) 2009 American Cancer Society.
Authors: Daniel P Petrylak; Donna Pauler Ankerst; Caroline S Jiang; Catherine M Tangen; Maha H A Hussain; Primo N Lara; Jeffrey A Jones; Mary Ellen Taplin; Patrick A Burch; Manish Kohli; Mitchell C Benson; Eric J Small; Derek Raghavan; E David Crawford Journal: J Natl Cancer Inst Date: 2006-04-19 Impact factor: 13.506
Authors: Laurence Collette; Tomasz Burzykowski; Kevin J Carroll; Don Newling; Tom Morris; Fritz H Schröder Journal: J Clin Oncol Date: 2005-09-01 Impact factor: 44.544
Authors: William K Oh; Julia Hayes; Carolyn Evan; Judith Manola; Daniel J George; Helen Waldron; Meaghan Donovan; John Varner; John Orechia; Beth Katcher; Diana Lu; Arthur Nevins; Renée L Wright; Lauren Tormey; James Talcott; Mark A Rubin; Massimo Loda; William R Sellers; Jerome P Richie; Philip W Kantoff; Jane Weeks Journal: Clin Genitourin Cancer Date: 2006-06 Impact factor: 2.872
Authors: Maha Hussain; Catherine M Tangen; Celestia Higano; Paul F Schelhammer; James Faulkner; E David Crawford; George Wilding; Atif Akdas; Eric J Small; Bryan Donnelly; Gary MacVicar; Derek Raghavan Journal: J Clin Oncol Date: 2006-08-20 Impact factor: 44.544
Authors: Andrew J Armstrong; Elizabeth Garrett-Mayer; Yi-Chun Ou Yang; Michael A Carducci; Ian Tannock; Ronald de Wit; Mario Eisenberger Journal: J Clin Oncol Date: 2007-09-01 Impact factor: 44.544
Authors: A V D'Amico; R Whittington; S B Malkowicz; D Schultz; K Blank; G A Broderick; J E Tomaszewski; A A Renshaw; I Kaplan; C J Beard; A Wein Journal: JAMA Date: 1998-09-16 Impact factor: 56.272
Authors: Betsan M Thomas; Christian Smith; Jessica Evans; Michael R Button; Satish Kumar; Nachi Palaniappan; John Staffurth; Jacob S Tanguay; Jason F Lester Journal: Med Oncol Date: 2013-09-12 Impact factor: 3.064
Authors: Mira A Patel; Marisa Kollmeier; Sean McBride; Daniel Gorovets; Melissa Varghese; Luanna Chan; Andrea Knezevic; Zhigang Zhang; Michael J Zelefsky Journal: Radiother Oncol Date: 2019-06-06 Impact factor: 6.280
Authors: S Hori; T Jabbar; N Kachroo; J C Vasconcelos; C N Robson; V J Gnanapragasam Journal: J Cancer Res Clin Oncol Date: 2011-02 Impact factor: 4.553